{"id":26622,"date":"2021-11-02T09:41:25","date_gmt":"2021-11-02T09:41:25","guid":{"rendered":"https:\/\/touchneurology.com\/?post_type=media_gallery&#038;p=26622"},"modified":"2021-11-02T09:41:45","modified_gmt":"2021-11-02T09:41:45","slug":"bernhard-hemmer-ectrims-2021-phase-3-antelope-study-results-investigating-natalizumab-biosimilar-pb006-in-rms","status":"publish","type":"media_gallery","link":"https:\/\/touchneurology.com\/multiple-sclerosis\/conference-hub\/bernhard-hemmer-ectrims-2021-phase-3-antelope-study-results-investigating-natalizumab-biosimilar-pb006-in-rms\/","title":{"rendered":"Bernhard Hemmer, ECTRIMS 2021: Phase 3 Antelope Study Results Investigating Natalizumab Biosimilar PB006 in RMS"},"content":{"rendered":"<p>touchNEUROLOGY met up with <strong>Prof. Bernhard Hemmer<\/strong> (TUM-Klinikum rechts der Isar, Munich, Germany) to discuss the primary data from the phase III Antelope study, investigating proposed natalizumab biosimilar PB006 in relapsing remitting multiple sclerosis.<\/p>\n<p>The abstract entitled: \u2018Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri\u00ae in patients with relapsing remitting multiple sclerosis: primary data from the phase III Antelope study\u2019 was presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 13-15 October 2021.<\/p>\n<p><strong>Questions<\/strong>:<\/p>\n<ol>\n<li>Why are biosimilar drugs needed in MS and what are the challenges in their production? (0:17)<\/li>\n<li>What were the aims and design of the Antelope study? (0:51)<\/li>\n<li>What were the efficacy and safety findings of the study? (1:18)<\/li>\n<li>What will be the next step in the clinical development of biosimilar natalizumab? (2:02)<\/li>\n<\/ol>\n<p><strong>Disclosures<\/strong>: Bernhard Hemmer has served on scientific advisory boards for Novartis; he has served as DMSC member for AllergyCare, Polpharma and TG therapeutics; he or his institution have received speaker honoraria from Desitin; his institution received research grants from Regeneron for multiple sclerosis research. Bernhard Hemmer holds part of two patents; one for the detection of antibodies against KIR4.1 in a subpopulation of patients with multiple sclerosis and one for genetic determinants of neutralizing antibodies to interferon. All conflicts are not relevant to the topic of the study.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch<\/p>\n<p><em><strong>Filmed as a highlight of ECTRIMS, Virtual 2021<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>touchNEUROLOGY met up with Prof. Bernhard Hemmer (TUM-Klinikum rechts der Isar, Munich, Germany) to discuss the primary data from the phase III Antelope study, investigating proposed natalizumab biosimilar PB006 in relapsing remitting multiple sclerosis. The abstract entitled: \u2018Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri\u00ae in patients with relapsing remitting multiple sclerosis: primary [&hellip;]<\/p>\n","protected":false},"featured_media":26623,"template":"","class_list":["post-26622","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-multiple-sclerosis","video_categories-ectrims-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/26622"}],"collection":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/26622\/revisions"}],"predecessor-version":[{"id":26625,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media_gallery\/26622\/revisions\/26625"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media\/26623"}],"wp:attachment":[{"href":"https:\/\/touchneurology.com\/wp-json\/wp\/v2\/media?parent=26622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}